Thursday, September 02, 2010

Genitourinary Cancer

CA 184-043
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel
CALGB-90203	Lead group: CALGB
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB-C90601
A Randomized Double-Blinded Phase III Study comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma.
E2805 (ASSURE)	Lead group: ECOG
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

We participate in many NCI sponsored trials. Please feel free to contact Leann Ross at (304) 399-6617 or leann.ross@chhi.org or Barbara Payne at (304) 399-6637.

For more information about the clinical trials listed please go to http://www.clinicaltrials.gov.